$2.58
-3.7%Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
NAUT โข NASDAQ
| Nautilus Biotechnology, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-59M | -70.8M | -63.7M | -57.9M | -50.3M | -15.6M | -9.6M | 626.6M | |
6.5M | 6.4M | 5.7M | 3.4M | 2.8M | 2.3M | 548K | 0.0 | |
6.8M | 12.7M | 12.1M | 10.4M | 7.9M | 369K | 110K | 0.0 | |
-1.4M | -2M | -2.7M | -890K | 320K | 295K | -157K | -866.2M | |
-3.6M | -5.5M | -3.2M | -788K | -22K | -1.4M | -545K | 1.3M | |
-50.7M | -59.1M | -51.7M | -45.8M | -39.2M | -14M | -9.7M | -238.3M | |
INVESTING ACTIVITIES | ||||||||
-1.3M | -2.1M | -2.4M | -2.3M | -2.3M | -921K | -926K | (0.0) | |
-72.5M | -86.3M | -112.9M | -186.6M | -221.8M | -68.4M | (0.0) | (0.0) | |
109M | 0.0 | 71.6M | 163.2M | 85.1M | 44M | 0.0 | 0.0 | |
0.0 | 154.7M | 0.0 | 0.0 | 0.0 | 0.0 | 5M | 1.2M | |
(35.2M) | (66.3M) | -43.7M | -25.7M | -139M | -25.3M | (4.1M) | (1.2M) | |
FINANCING ACTIVITIES | ||||||||
214K | 1.1M | 368K | 562K | -8M | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -874.3K | -1.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 335.4M | 42K | 36K | 145.2B | |
214K | 1.1M | 368K | 562K | 327.4M | 75.9M | 36K | 145.2B | |
CASH FLOW SUMMARY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -144.9B | |
-15.3M | 8.2M | -95.1M | -71M | 149.2M | 36.6M | 595K | 1.2M | |
28.6M | 20.4M | 115.5M | 186.5M | 37.2M | 595K | 1.2M | 0.0 | |
13.4M | 28.6M | 20.4M | 115.5M | 186.5M | 37.2M | 595K | 1.2M | |
-52M | -61.3M | -54.2M | -48.1M | -41.5M | -14.9M | -10.6M | -238.3M |
NAUT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 28, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 28, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | July 31, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 31, 2025 | July 31, 2025 | 2025 |
Continue your NAUT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.